Sep 12th 2012 - Edison Investment Research today published a report on Innate Pharma entitled "Boosting Innate Immunity". In summary, the report says:
Innate Pharma’s investment case depends on clinical development milestones being achieved with its two lead products, IPH2102 in Phase II for cancer and IPH2201 in Phase I for inflammatory diseases, which have been licensed to Bristol-Myers Squibb (BMS) and Novo Nordisk respectively. Innate has another two products in preclinical studies. The company uses its deep knowledge of innate immunity to develop treatments with novel mechanisms of action, which have significant potential in oncology and inflammatory indications. Proof of concept data with IPH2101 or details of BMS’s clinical programme could lead to a re-rating of Innate’s shares.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »